Tonix Pharmaceuticals, food and drug administration
Tonix Pharmaceuticals Gets FDA Review of Fibromyalgia Drug
Tonix Pharmaceuticals Holding said the Food and Drug Administration has accepted its application seeking approval of its TNX-102 SL product candidate for the chronic pain condition fibromyalgia. Tonix on Tuesday said it expects the FDA to communicate a target action date and a decision on whether to grant priority review to the application in a so-called "Day 74" letter,
The Richmond company (Nasdaq: BIOA) will get a fraction of the money upfront from Novartis (NYSE: NVS) — up to $20 million, ...
for the ketamine Abbreviated New Drug Application, which was assigned a Generic Drug User Fee Amendments of 2022 (“GDUFA”) goal date of October 29, 2024. The Company has initiated activities ...
Even though AI-designed drugs aren’t yet a household term for FDA-approved, commercially available therapies, they are a ...
LONDON - A new class of weight loss drugs developed by Novo Nordisk and Eli Lilly “opens the possibility of an end to the ...
(ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company advancing treatments for neurodegenerative diseases, is pleased to announce the filing of an Investigational New Drug ...
Shares of Aldeyra Therapeutics gained after the Food and Drug Administration accepted the company's resubmitted new drug application for its treatment of dry eye disease for review. The stock rose ...
Granules Pharmaceuticals, Inc (GPI) has received approval from the US Food & Drug Administration (USFDA) for its abbreviated ...
Limited announces that the U.S. Food and Drug Administration, FDA, has approved its suitability petition for a new animal drug ...
Executives at a local company believe they have a quicker and less expensive path to get their new drug approved.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback